Canadian patients living with several chronic inflammatory diseases have gained another treatment-delivery option after Health Canada approved Biocon's Yesintek autoinjector pen on July 29.

The approval covers Yesintek, a ustekinumab biosimilar, in 45 mg/0.05 mL and 90 mg/mL autoinjector strengths. The new format adds to Yesintek products already approved in Canada.

Yesintek is used for conditions including moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn's disease and ulcerative colitis. Its psoriasis indication also includes certain pediatric patients aged 6 to 17.

The new autoinjector is notable because it provides a different self-administration format, potentially offering greater flexibility for patients and health-care providers depending on treatment needs and care settings. Biocon said the format is not currently offered by the originator product in Canada.

The approval also adds to Canada's growing biosimilar medicines market, which is increasingly important as health systems look for treatment options that can improve access and potentially reduce costs.

Health Canada's existing product database lists Yesintek among approved products, while Biocon previously received Canadian authorization for other Yesintek formulations in 2025.

The latest approval does not mean every patient will automatically receive the autoinjector. Treatment decisions, availability and coverage can vary, so patients should discuss appropriate options with their health-care professionals.

For Canada's health sector, the development represents another step toward expanding biosimilar treatment choices and patient-friendly drug delivery options for people managing long-term inflammatory diseases.